The present invention relates to a neurodegenerative disease therapeutic agent, and, more specifically, provides a composition containing, as an active ingredient, an ALK (anaplastic lymphoma kinase) activity or expression inhibiting substance in order to treat a degenerative brain disease caused by the phosphorylation or coagulation of tau proteins.La présente invention concerne un agent thérapeutique destiné à une maladie neurodégénérative et, plus particulièrement, consiste en une composition contenant, comme principe actif, une substance inhibant lactivité ou lexpression dALK (kinase du lymphome anaplasique) en vue de traiter une maladie cérébrale dégénérative provoquée par la phosphorylation ou la coagulation de protéines tau.본 발명은 신경 퇴행성 질환 치료제에 관한 것으로서, 보다 구체적으로 타우 단백질의 인산화 또는 응집으로 인해 발생하는 퇴행성 뇌질환을 치료하기 위하여 ALK(anaplastic lymphoma kinase)의 활성 또는 발현 저해물질을 유효성분으로 함유하는 조성물을 제공한다.
